Results 161 to 170 of about 584,120 (299)

The ABCs of donor selection: Availability Before Compatibility? [PDF]

Haematologica
Shaffer BC, Perales MA.
europepmc   +1 more source

Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients. [PDF]

Melanoma Res, 2023
Fortman D, Avellan MGP, Hurd D, Schwartz M, Dubner H, Hewitt C, Berton S, Ernst S, Rose A, Zarour HWH, Davar D.   +10 more
europepmc   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

Donor selection, graft engineering, and dosing oh my! [PDF]

Hematology Am Soc Hematol Educ Program
Moskop A, Talano JA.
europepmc   +1 more source

A Matching Strategy To Guide Donor Selection for Ulcerative Colitis in Fecal Microbiota Transplantation: Meta-Analysis and Analytic Hierarchy Process. [PDF]

Microbiol Spectr, 2023
Zhang B, Yang L, Ning H, Cao M, Chen Z, Chen Q, Lian G, Tang H, Wang Q, Wang J, Lin Z, Wen J, Liu Y, Xuan J, Li X, Lin A, He J, Zhang L, Hou X, Zeng Q, Xiao C.   +20 more
europepmc   +1 more source

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

Molecular Oncology, EarlyView.
COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann, Eduardo García‐Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd, Ian Miller, Janick Selves, Nadja Meindl‐Beinker, Fiorella Ruiz‐Pace, Elena Élez, Raquel Comas‐Navarro, Frank Lincoln, Dirk Fey, Gift Nyamundanda, Aoife Nolan, Joern Lewin, Raquel Perez‐Lopez, Jonathan Briody, Kathleen Bennett, Walter Kolch, David Matallanas, Alexander Kel, Enrique Arenas, Joaquín Arribas, Bart Ghesquière, Josep Tabernero, Julie Meilleroux, Deborah McNamara, Ray McDermott, Marvin Lim, Mary O'Reilly, Brian Bird, Lisa Stack, Lucia Moloney, Patrick Morris, Keith Egan, Maciej Milewski, Lars Scheuer, Joachim Behringer, Georg Bolz, Ramon Salazar, Cristina Santos, Andrea Ruiz, Orla Casey, Verena Murphy, Matthias Ebert, Livio Trusolino, Diether Lambrechts, Anguraj Sadanandam, Catherine Sautès‐Fridman, Jochen Prehn, Paolo Nuciforo, Jacques Fieschi, Florence Monville, Darran O'Connor, Wolf Fridman, Annette Byrne   +61 more
wiley   +1 more source

Donor selection for patients with HLA-homozygous haplotypes in allogeneic hematopoietic stem cell transplantation. [PDF]

Ann Hematol
Yoshinaga N, Iwasaki M, Kato K, Kimura F, Hirayama M, Kanaya M, Morishima S, Uchida N, Doki N, Fukuda T, Kanda Y, Nishida T, Hasegawa Y, Kako S, Tanaka M, Kurokawa M, Asada N, Kawakita T, Kataoka K, Kondo Y, Imada K, Ichinohe T, Onizuka M, Atsuta Y, Kanda J.   +24 more
europepmc   +1 more source

Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation? [PDF]

Br J Haematol, 2022
Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S.   +19 more
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection. [PDF]

Leukemia
Mehta RS, McCurdy SR, Milano F, Nawas M, Aljawai Y, Rimando JC, Al-Juhaishi T, Im A, Kanakry JA, Lazaryan A, Kanakry CG.   +10 more
europepmc   +1 more source